Literature DB >> 16793534

Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases.

V Prakash Reddy1, Ayse Beyaz.   

Abstract

The Maillard reaction is a complex series of reactions that involve reducing-sugars and proteins, giving a multitude of end-products that are known as advanced glycation end-products (AGEs). AGEs can contribute to the pathogenesis of diabetes and neurological diseases such as Alzheimer's disease. AGEs also play a major role in vascular stiffening, atherosclerosis, osteoarthritis, inflammatory arthritis and cataracts. Thus, AGE inhibitors and AGE breakers offer a potential strategy as therapeutics for diverse diseases. Various AGE inhibitors have been developed in recent years, and their underlying mechanism is based on the attenuation of glycoxidation and/or oxidative stress by the sequestration of metal ions, reactive 1,2-dicarbonyl compounds, and reactive oxygen and reactive nitrogen species.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16793534     DOI: 10.1016/j.drudis.2006.05.016

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  47 in total

1.  Antioxidant and antiglycating activities of Salvia sahendica and its protective effect against oxidative stress in neuron-like PC12 cells.

Authors:  Fatemeh Shaerzadeh; Abolhassan Ahmadiani; Mohammad Ali Esmaeili; Niloufar Ansari; Sareh Asadi; Solaleh Khoramian Tusi; Ali Sonboli; Mina Ghahremanzamaneh; Fariba Khodagholi
Journal:  J Nat Med       Date:  2011-03-18       Impact factor: 2.343

Review 2.  Advanced glycation end products, diabetes and ageing.

Authors:  N Nass; B Bartling; A Navarrete Santos; R J Scheubel; J Börgermann; R E Silber; A Simm
Journal:  Z Gerontol Geriatr       Date:  2007-10       Impact factor: 1.281

Review 3.  Prevention of non-enzymatic glycosylation (glycation): Implication in the treatment of diabetic complication.

Authors:  H Younus; S Anwar
Journal:  Int J Health Sci (Qassim)       Date:  2016-04

Review 4.  Revisiting amino acids and peptides as anti-glycation agents.

Authors:  H Chilukuri; M J Kulkarni; M Fernandes
Journal:  Medchemcomm       Date:  2018-02-12       Impact factor: 3.597

5.  Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats.

Authors:  Olaf Brouwers; Petra M Niessen; Isabel Ferreira; Toshio Miyata; Peter G Scheffer; Tom Teerlink; Patrick Schrauwen; Michael Brownlee; Coen D Stehouwer; Casper G Schalkwijk
Journal:  J Biol Chem       Date:  2010-11-05       Impact factor: 5.157

6.  Inhibiting Effect of Zinc Oxide Nanoparticles on Advanced Glycation Products and Oxidative Modifications: a Potential Tool to Counteract Oxidative Stress in Neurodegenerative Diseases.

Authors:  Jalaluddin M Ashraf; Mohammad Azam Ansari; Sana Fatma; Saleh M S Abdullah; Johar Iqbal; Aymen Madkhali; Al Hassan Hamali; Saheem Ahmad; Ahmed Jerah; Valentina Echeverria; George E Barreto; Ghulam Md Ashraf
Journal:  Mol Neurobiol       Date:  2018-02-08       Impact factor: 5.590

Review 7.  Nitroxidized-Albumin Advanced Glycation End Product and Rheumatoid Arthritis.

Authors:  Akhlas Tarannum; Zarina Arif; Khursheed Alam; Shafeeque Ahmad; Moin Uddin
Journal:  Arch Rheumatol       Date:  2019-04-22       Impact factor: 1.472

8.  Glycation of the muscle-specific enolase by reactive carbonyls: effect of temperature and the protection role of carnosine, pyridoxamine and phosphatidylserine.

Authors:  Jadwiga Pietkiewicz; Agnieszka Bronowicka-Szydełko; Katarzyna Dzierzba; Regina Danielewicz; Andrzej Gamian
Journal:  Protein J       Date:  2011-03       Impact factor: 2.371

9.  Effects of a new advanced glycation inhibitor, LR-90, on mitigating arterial stiffening and improving arterial elasticity and compliance in a diabetic rat model: aortic impedance analysis.

Authors:  S Satheesan; J L Figarola; T Dabbs; S Rahbar; R Ermel
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

Review 10.  Oxidative stress in diabetes and Alzheimer's disease.

Authors:  V Prakash Reddy; Xiongwei Zhu; George Perry; Mark A Smith
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.